摘要
摘要
The disease burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represents an unmet need for pharmacotherapies to halt progression or reverse fibrosis. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are the first to be approved for chronic obesity management and diabetes to be examined in individuals with MASLD/MASH. Successful phase 2 and phase 3 randomized control trials have shown indirect improvements in liver fat, histology, and biomarkers. Over the last few years, newer agents with glucose-dependent insulinotropic peptide agonism and/or glucagon receptor agonism have shown considerable improvements in liver fat content and histology in phase 2 studies. Based on the mounting evidence, single, dual, and triple incretin receptor agonists are promising agents in the treatment of MASLD. In this narrative review, we evaluate weight loss pharmacotherapy for MASLD and then explore the potential for a "positive" disruption that these agents will bring to the existing management of MASLD in patients with obesity.
KM 提取结果
0 个 Figure · 0 个 KM 面板